Marquita Nettles
Nurse Practitioner · Mobile, ALNPI 1164283297
Payments from drug & device makers
Across 157 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$494
- AbbVie$491
- E.r. Squibb & Sons, L.L.C.$436
- Axsome Therapeutics, Inc.$333
- Teva Pharmaceuticals USA, Inc.$317
- Otsuka America Pharmaceutical, Inc.$302
- plus $851 from 11 others
What the payments were for
- Food & beverage$3,224100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $494 |
| AbbVie | 54 | $491 |
| E.r. Squibb & Sons, L.L.C. | 19 | $436 |
| Axsome Therapeutics, Inc. | 14 | $333 |
| Teva Pharmaceuticals USA, Inc. | 4 | $317 |
| Otsuka America Pharmaceutical, Inc. | 6 | $302 |
| Neurocrine Biosciences, Inc. | 7 | $150 |
| Supernus Pharmaceuticals, Inc. | 8 | $142 |
| Lundbeck LLC | 6 | $108 |
| Johnson & Johnson | 4 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Vanda Pharmaceuticals Inc. | 4 | $88 |
| Corium, LLC | 4 | $60 |
| Neos Therapeutics, LP | 2 | $43 |
| Alkermes, Inc. | 1 | $25 |
| Tris Pharma Inc | 1 | $21 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$269
- COBENFY$255
- CAPLYTA$253
- Auvelity$124
- REXULTI$122
How this compares
$3,224 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $94,612 |
| RexultiBrexpiprazole | 12 | $17,721 |
| Vilazodone Hcl | 21 | $3,504 |
| Lurasidone Hcl | 13 | $2,129 |
| Bupropion XlBupropion Hcl | 26 | $652 |
| Buspirone Hcl | 28 | $303 |
| Mirtazapine | 16 | $302 |
| Lamotrigine | 25 | $246 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $203 |
| Olanzapine | 17 | $160 |
| Quetiapine Fumarate | 17 | $145 |
| Escitalopram Oxalate | 15 | $108 |
| Trazodone Hcl | 29 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $150 | $94,61211 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $302 | $17,72112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Mobile
- Ardie Pack MabienMobile$126K
- Wilma BaliemMobile$13K
- Erin RiscoMobile$11K
- Hope TindleMobile$9K
- Erin TannerAlabaster$141K
- Ginger McDanielBirmingham$27K
- Audrey MorganMontgomery$24K
- Hollie CrutchfieldDothan$22K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.